Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in conjunction with the Pancreatic Cancer Research Team and Cancer Research And Biostatistics.
Published today in the Journal of the American Medical Association (JAMA) Oncology, researchers found that among a clinical trial of 25 patients, adding the drug cisplatin to a current standard-of-care drug regimen resulted in substantial tumor shrinkage for 71 percent of those patients, and dramatically increased survival beyond one year. Read more . . .